{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-22-000117","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2022-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.844972+00:00","generated_at":"2026-06-23T02:24:45.041429+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xeris reports positive Phase 1 data for SC levothyroxine (XP-8121); weekly dosing matches daily oral","bullets":["Phase 1 study (n=60) shows proof-of-concept for once-weekly SC XP-8121 with steady-state exposure similar to daily oral Synthroid.","Population PK model implies dose conversion factor of 4X: weekly 1200 μg SC equivalent to daily 300 μg PO levothyroxine.","XP-8121 well tolerated at all doses (600, 1200, 1500 μg); safety profile comparable to Synthroid 600 μg PO.","Company expects FDA End-of-Phase 1 meeting feedback by end of 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-22-000117","json":"https://secwatch.observer/filing/0001867096-22-000117.json","markdown":"https://secwatch.observer/filing/0001867096-22-000117.md","text":"https://secwatch.observer/filing/0001867096-22-000117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000117/0001867096-22-000117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000117/xers-20221020.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T02:24:45.041429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}